Filing Details
- Accession Number:
- 0001725914-18-000004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-12-06 16:23:25
- Reporting Period:
- 2018-12-06
- Accepted Time:
- 2018-12-06 16:23:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
926617 | Vermillion Inc. | VRML | In Vitro & In Vivo Diagnostic Substances (2835) | 330595156 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1725914 | Harry Robert Beechey | C/O Vermillion, Inc. 12117 Bee Caves Rd, Bldg 3 Ste 100 Austin TX 78738 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2018-12-06 | 25,000 | $0.57 | 200,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.567 to $0.572 per share. The reporting person undertakes to provide to Vermillion, any security holder of Vermillion or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.